| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2500-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2500-25
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2500-90
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2500-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2533-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-115
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-91
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2509-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2533-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2506-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2500-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-392 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-079
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-12 |
| filingDate |
2004-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2006-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2006526997-A |
| titleOfInvention |
Promotion of oligodendrocyte differentiation |
| abstract |
The present invention is generally in the field of nervous system diseases and neurological diseases, and in particular in the field of neurodegenerative diseases where the myelin coating of the nerve is lost. IL6R / IL6 chimeras are used to promote the formation of embryonic stem cell-derived oligodendrocytes for the treatment of neurodegenerative diseases or injury following neurotrauma. |
| priorityDate |
2003-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |